CR20200564A - Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos - Google Patents

Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos

Info

Publication number
CR20200564A
CR20200564A CR20200564A CR20200564A CR20200564A CR 20200564 A CR20200564 A CR 20200564A CR 20200564 A CR20200564 A CR 20200564A CR 20200564 A CR20200564 A CR 20200564A CR 20200564 A CR20200564 A CR 20200564A
Authority
CR
Costa Rica
Prior art keywords
monospecific
multispecific anti
tmeff2 antibodies
antibodies
tmeff2
Prior art date
Application number
CR20200564A
Other languages
English (en)
Spanish (es)
Inventor
Phillip Cooper
Colleen Kane
Robin Ernst
Sanjaya Singh
Sheng-Jiun Wu
Michael Russell
Rajkumar Ganesan
Sathyadevi Venkataramani
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CR20200564A publication Critical patent/CR20200564A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20200564A 2018-05-24 2019-05-21 Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos CR20200564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862675957P 2018-05-24 2018-05-24
PCT/IB2019/054184 WO2019224713A2 (en) 2018-05-24 2019-05-21 Monospecific and multispecific anti-tmeff2 antibodies and there uses

Publications (1)

Publication Number Publication Date
CR20200564A true CR20200564A (es) 2021-06-21

Family

ID=67211771

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200564A CR20200564A (es) 2018-05-24 2019-05-21 Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos

Country Status (25)

Country Link
US (1) US11866499B2 (https=)
EP (1) EP3802607A2 (https=)
JP (2) JP2021524255A (https=)
KR (1) KR20210011999A (https=)
CN (1) CN112703203B (https=)
AR (1) AR115419A1 (https=)
AU (1) AU2019274652B2 (https=)
BR (1) BR112020023416A2 (https=)
CA (1) CA3101304A1 (https=)
CL (1) CL2020003032A1 (https=)
CO (1) CO2020014515A2 (https=)
CR (1) CR20200564A (https=)
EA (1) EA202092849A1 (https=)
EC (1) ECSP20075234A (https=)
IL (1) IL278862A (https=)
JO (1) JOP20200295A1 (https=)
MA (1) MA52772A (https=)
MX (1) MX2020012589A (https=)
NI (1) NI202000087A (https=)
PE (1) PE20210634A1 (https=)
PH (1) PH12020551948A1 (https=)
SG (1) SG11202011268VA (https=)
TW (1) TWI865451B (https=)
UY (1) UY38243A (https=)
WO (1) WO2019224713A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof
CA3164972A1 (en) * 2019-12-18 2021-06-24 Janssen Biotech, Inc. Materials and methods for in vivo biological targeting
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
US20230374140A1 (en) * 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
TW202231292A (zh) 2020-10-13 2022-08-16 美商健生生物科技公司 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
CA3266816A1 (en) * 2022-09-09 2024-03-14 Janssen Biotech, Inc. CANCER TREATMENT METHOD WITH AN ANTI-TMEFF2XCD3 BISPECIFIC ANTIBODY

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
KR101104655B1 (ko) * 2002-03-08 2012-01-13 애보트 바이오테라퓨틱스 코포레이션 암 항원 ｔｍｅｆｆ２ 에 대한 항체 및 이의 용도
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
MX2010003718A (es) * 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2013093122A2 (en) * 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
HRP20231356T1 (hr) 2012-12-14 2024-02-16 Omniab, Inc. Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
KR102216003B1 (ko) 2013-03-15 2021-02-16 얀센 바이오테크 인코포레이티드 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JO3568B1 (ar) 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
EP3778640A1 (en) 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3370768B9 (en) * 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
US12012461B2 (en) * 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2021524255A (ja) 2021-09-13
KR20210011999A (ko) 2021-02-02
US11866499B2 (en) 2024-01-09
JOP20200295A1 (ar) 2020-11-22
WO2019224713A2 (en) 2019-11-28
EP3802607A2 (en) 2021-04-14
US20190359711A1 (en) 2019-11-28
AR115419A1 (es) 2021-01-13
BR112020023416A2 (pt) 2021-02-17
UY38243A (es) 2019-11-29
JP2024105476A (ja) 2024-08-06
TW202003584A (zh) 2020-01-16
ECSP20075234A (es) 2020-12-31
CN112703203A (zh) 2021-04-23
WO2019224713A3 (en) 2020-01-02
PH12020551948A1 (en) 2021-08-16
CA3101304A1 (en) 2019-11-28
TWI865451B (zh) 2024-12-11
AU2019274652B2 (en) 2026-03-26
CL2020003032A1 (es) 2021-04-16
EA202092849A1 (ru) 2021-03-16
NI202000087A (es) 2021-03-23
MX2020012589A (es) 2021-01-29
CO2020014515A2 (es) 2020-12-10
MA52772A (fr) 2021-04-14
IL278862A (en) 2021-01-31
PE20210634A1 (es) 2021-03-23
AU2019274652A1 (en) 2020-11-26
CN112703203B (zh) 2025-02-25
SG11202011268VA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
PH12019502283A1 (en) Anti-lag3 antibodies
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2019007021A (es) Anticuerpos il-11ra.
PH12016501763B1 (en) Multispecific antibodies
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
ZA201703510B (en) Antibodies, uses & methods
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
MY190659A (en) Method for producing biohydrocarbons
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
EA201990270A1 (ru) Смеси, содержащие defi и тауратамиды, и способы их получения